The Problem

Addressing Critical Unmet Medical Needs

Key Challenges

High costs, long durations, and regulatory complexity concentrate innovation in wealthy nations.

Limited capacity and misaligned incentives at current costs.

Rare/neglected diseases receive little focus; access and affordability remain limited.

The Scale of the Problem

9,000+
Identified diseases
≈90%
Diseases without approved therapies
400M+
People with rare diseases (global)
$8T
US direct & indirect costs of rare diseases
$240k/year
Average US treatment cost (rare diseases)

Understanding the Impact

New drug development requires significant capital and faces uncertain recovery of sunk costs. The result is a narrow focus on profitable widespread indications, widening disparities in access and affordability and creating systemic inefficiencies in care.

There's a Better Way

Our LADR4 platform addresses these fundamental challenges by dramatically reducing time, cost, and risk while improving success rates.

4x Faster

Development time reduced dramatically

98% Cost Reduction

From billions to millions

Higher Success Rate

Proven track record